Next Article in Journal / Special Issue
Therapy of Skin, Hair and Nail Fungal Infections
Previous Article in Journal / Special Issue
Treatment of Invasive Candidiasis: A Narrative Review
Article Menu
Issue 3 (September) cover image

Export Article

Open AccessReview
J. Fungi 2018, 4(3), 98; https://doi.org/10.3390/jof4030098

Treatment of Aspergillosis

1
Department of Medicine, University of California–San Diego, San Diego, CA 92103, USA
2
Division of Infectious Diseases, Department of Medicine, University of California–San Diego, San Diego, CA 92103, USA
3
Section of Infectious Diseases and Tropical Medicine and Division of Pulmonology, Medical University of Graz, Graz 8036, Austria
*
Author to whom correspondence should be addressed.
Received: 24 July 2018 / Revised: 12 August 2018 / Accepted: 15 August 2018 / Published: 19 August 2018
(This article belongs to the Special Issue Treatments for Fungal Infections)
Full-Text   |   PDF [316 KB, uploaded 19 August 2018]

Abstract

Infections caused by Aspergillus spp. remain associated with high morbidity and mortality. While mold-active antifungal prophylaxis has led to a decrease of occurrence of invasive aspergillosis (IA) in those patients most at risk for infection, breakthrough IA does occur and remains difficult to diagnose due to low sensitivities of mycological tests for IA. IA is also increasingly observed in other non-neutropenic patient groups, where clinical presentation is atypical and diagnosis remains challenging. Early and targeted systemic antifungal treatment remains the most important predictive factor for a successful outcome in immunocompromised individuals. Recent guidelines recommend voriconazole and/or isavuconazole for the primary treatment of IA, with liposomal amphotericin B being the first alternative, and posaconazole, as well as echinocandins, primarily recommended for salvage treatment. Few studies have evaluated treatment options for chronic pulmonary aspergillosis (CPA), where long-term oral itraconazole or voriconazole remain the treatment of choice. View Full-Text
Keywords: Aspergillus; posaconazole; amphotericin; isavuconazole; voriconazole; itraconzole; invasive aspergillosis; chronic pulmonary aspergillosis; diagnosis; interleukin 8 Aspergillus; posaconazole; amphotericin; isavuconazole; voriconazole; itraconzole; invasive aspergillosis; chronic pulmonary aspergillosis; diagnosis; interleukin 8
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).
SciFeed

Share & Cite This Article

MDPI and ACS Style

Jenks, J.D.; Hoenigl, M. Treatment of Aspergillosis. J. Fungi 2018, 4, 98.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
J. Fungi EISSN 2309-608X Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top